RUZILAWATI ABU BAKAR

Dr. RUZILAWATI ABU BAKAR

Universiti Sains Malaysia
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2007 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
RBRUZILAWATI ABU BAKAR
RUZILAWATI ABU BAKAR
MWMohd Suhaimi Abd. Wahab
Mohd Suhaimi Abd. Wahab
IAIMRAN AHMAD
IMRAN AHMAD
ZIZabidah Ismail
Zabidah Ismail
MIMd Asiful Islam
Md Asiful Islam

18 May 2007 in Clinica Chimica Acta
Verified
Journal Article
Closed access
RBRUZILAWATI ABU BAKAR
RUZILAWATI ABU BAKAR
ASA.W. Mohd Suhaimi
A.W. Mohd Suhaimi
MIMd Asiful Islam
Md Asiful Islam

6 September 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MZMOHD SHAFIE ZABIDI
MOHD SHAFIE ZABIDI
RBRUZILAWATI ABU BAKAR
RUZILAWATI ABU BAKAR
NMNurfadhlina Musa
Nurfadhlina Musa
SMSuzana Mustafa
Suzana Mustafa
WYWan Nazirah Wan Yusuf
Wan Nazirah Wan Yusuf
Understanding the pharmacokinetics parameter of colistin methanesulfonate sodium (CMS) and colistin is needed to optimize the dosage regimen in critically ill patients. However, there is a scarcity of pharmacokinetics parameters in this population. This review provides a comprehensive understanding of CMS and colistin pharmacokinetics parameters in this population. The relevant studies published in English that reported on the pharmacokinetics of CMS and colistin from 2000 until 2020 were systematically searched using the PubMed and Scopus electronic databases. Reference lists of articles were reviewed to identify additional studies. A total of 252 citation titles were identified, of which 101 potentially relevant abstracts were screened, and 25 full-text articles were selected for detailed analysis. Of those, 15 studies were included for the review. This review has demonstrated vast inter-study discrepancies in colistin plasma concentration and the pharmacokinetics parameter estimates. The discrepancies might be due to complex pathophysiological changes in the population studied, differences in CMS brand used, methodology, and study protocol. Application of loading dose of CMS and an additional dose of CMS after dialysis session was recommended by some studies. In view of inter-patient and intra-patient variability in colistin plasma concentration and pharmacokinetics parameters, personalized colistin dosing for this population is recommended.

20 April 2022 in PeerJ
Verified
Journal Article
Open access
PDF file
INIsmail Che Noh
Ismail Che Noh
RARichard Avoi
Richard Avoi
ANAsma Abdullah Nurul
Asma Abdullah Nurul
IAImran Ahmad
Imran Ahmad
RBRUZILAWATI ABU BAKAR
RUZILAWATI ABU BAKAR
Background: Chronic hepatitis C virus (HCV) infection is one of the major causes of liver cirrhosis and liver carcinoma. Studies have indicated that an imbalance of cytokine activities could contribute to the pathogenesis of chronic HCV infection. This study aimed to investigate serum levels and gene expression of cytokines (IL-6, TNF-α and TGF-β1) in chronic HCV infection among Malay male subjects. Methods: Thirty-nine subjects were enrolled from various health clinics in Kelantan, Malaysia, and divided into two groups: patients with chronic HCV infection (HP) and healthy control (HS). The serum cytokines IL-6, TNF-a—were measured using Luminex assay, and serum TGF-β1 was measured by ELISA. The mRNA gene expression for IL-6, TNF-α and TGF-β1 was measured by real-time reverse transcriptase polymerase chain reaction (RT-PCR). Results: There were statistically significant differences in the mean serum levels of IL-6, and TGF-β1 in HP compared to HS group (p = 0.0180 and p = 0.0005, respectively). There was no significant difference in the mean serum level of TNF-α in HP compared to HS group. The gene expression for the studied cytokines showed no significant differences in HP compared to HS group. Conclusion: Serum IL-6 was significantly associated with chronic HCV infection.

4 June 2010 in Pharmacology
Verified
Journal Article
Closed access
RBRUZILAWATI ABU BAKAR
RUZILAWATI ABU BAKAR
MIMd Asiful Islam
Md Asiful Islam
Aim: To investigate the effects of CYP3A4 and CYP2C8 enzymes on repaglinide’s pharmacokinetics in healthy Malaysian subjects. Methods: Subjects (n = 121) received oral repaglinide (4 mg). Blood samples were taken at 0, 30, 60, 120, 180 and 240 min and serum concentrations of repaglinide were determined using high-performance liquid chromatography. Subjects were also genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for CYP3A4*4, *5 and*18 and by an allele-specific multiplex PCR for CYP2C8*2, *3, *4 and *5 alleles. Results: The allele frequencies of CYP2C8*1, *2, *3, *4 and *5 were 95.04, 0.40, 0.40, 0 and 4.13%, respectively. The frequencies of the CYP3A4*1, *4, *5 and *18 alleles were 97.93, 0, 0 and 2.07%, respectively. CYP2C8 and CYP3A4 genotypes were not significantly associated with repaglinide’s blood glucose-lowering effect. However, the CYP3A4 genotype significantly influenced some of repaglinide’s pharmacokinetics, where the mean elimination rate constant was 44.0% lower (p = 0.04) and the mean half-life was 33.8% higher (p = 0.04) in subjects with the CYP3A4*1/*18 genotype as compared to those with the normal CYP3A4*1/*1 genotype. This result confirms that CYP3A4 plays a large role in metabolizing repaglinide. Conclusion: Genetic polymorphisms of CYP3A4, specifically CYP3A4*18, play a major role in contributing to the interindividual variability in repaglinide’s pharmacokinetics.

10 June 2021 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
SAShafreena Shaukat Ali
Shafreena Shaukat Ali
LNLiza Noordin
Liza Noordin
RBRUZILAWATI ABU BAKAR
RUZILAWATI ABU BAKAR
SZSatirah Zainalabidin
Satirah Zainalabidin
ZJZakiah Jubri
Zakiah Jubri
WAWan Amir Nizam Wan Ahmad
Wan Amir Nizam Wan Ahmad